Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 02, 2025 09:20 ET | Source: Research and Markets

Europe At-home Respiratory Care Services Trends Analysis Report 2025-2033: Smart Inhalers, Connected Nebulizers and Mobile Apps Revolutionizing the Burgeoning Market

Dublin, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The "Europe At-home Respiratory Care Services Market Size, Share & Trends Analysis Report by Therapy (Oxygen Therapy, Non-Invasive Ventilation), by...
August 08, 2025 04:02 ET | Source: Research and Markets

Sleep Apnea Market Analysis Report 2025 | a Saturated Market of Generic Drugs with 27 Pipeline Molecules 336 Clinical Trials

Dublin, Aug. 08, 2025 (GLOBE NEWSWIRE) -- The "Sleep Apnea: Market View" report has been added to ResearchAndMarkets.com's offering.This reports provides a data-driven overview of the current and...
June 12, 2025 07:30 ET | Source: Incannex Healthcare

Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

NEW YORK and MELBOURNE, Australia, June 12, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing...
June 03, 2025 07:30 ET | Source: Incannex Healthcare

Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

NEW YORK and MELBOURNE, Australia, June 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company leading the way...
May 30, 2025 05:41 ET | Source: Research and Markets

Sleep Apnea Oral Appliances Market - Global Forecast to 2030 with SomnoMed, Resmed, ProSomnus, DynaFlex, Vivos Therapeutics, and OpenAirway Leading

Dublin, May 30, 2025 (GLOBE NEWSWIRE) -- The "Sleep Apnea Oral Appliances Market by Product (Mandibular Advancement Devices (MAD), Tongue-Retaining Devices (TRD)), Purchase Type...
May 29, 2025 07:30 ET | Source: Incannex Healthcare

Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance

NEW YORK and MELBOURNE, Australia, May 29, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing novel combination therapies, today...
May 28, 2025 07:00 ET | Source: Incannex Healthcare

Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results

MELBOURNE, Australia and NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing combination drug therapies for...
May 20, 2025 07:30 ET | Source: Incannex Healthcare

Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution

NEW YORK and MELBOURNE, Australia, May 20, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company pioneering the...
May 15, 2025 08:00 ET | Source: Incannex Healthcare

Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates

NEW YORK and MELBOURNE, Australia, May 15, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral...
May 14, 2025 08:00 ET | Source: Incannex Healthcare

Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA.End-of-study follow-up assessments on track for completion by May 17, 2025.Topline...